Genmab Reports Strong H1 2025 Results Driven By Higher Royalties And Product Sales

Genmab A/S reported robust first-half 2025 performance, with revenue climbing 19% year-over-year to $1.64 billion, largely propelled by a 24% increase in royalty revenue from key collaborations, notably strong global sales of DARZALEX, and higher EPKINLY product sales. Despite a decline in net financial income due to lower foreign exchange gains and interest income, the company's operational strength resonated positively with investors, as GMAB shares traded up 5.51% on the Nasdaq following the announcement.

Analysis

Genmab A/S (GMAB) reported a robust financial performance for the first half of 2025, demonstrating significant top-line momentum. Revenue grew 19% year-over-year to $1.64 billion, a gain primarily fueled by the strength of its royalty-based collaborations. Royalty revenue itself surged 24% to $1.38 billion, underscored by the impressive 22% increase in global net sales of DARZALEX by partner Johnson & Johnson, which reached $6.78 billion. Contributions from Novartis's Kesimpta and higher net product sales of Genmab's own EPKINLY further bolstered this operational strength. This core operational growth, however, was partially offset by a notable decline in net financial income to $119 million from $204 million, attributed to lower foreign exchange gains and reduced interest income. The market reacted positively to the operational results, with GMAB's stock climbing 5.51%, indicating investors are currently prioritizing the strong underlying fundamentals and royalty stream growth over the non-operational financial income headwinds.

Key Decisions for Investors

• Investors should recognize the strength of Genmab's core business, as the 19% revenue growth is driven by high-quality, recurring royalty streams from key pharmaceutical partners, suggesting a durable and scalable model.
• It is crucial to monitor the continued sales performance of partnered drugs, particularly DARZALEX by Johnson & Johnson, as this remains the primary driver of Genmab's financial results and valuation.
• The significant decline in net financial income warrants attention; investors should assess whether this is a temporary headwind due to macroeconomic factors like foreign exchange or a more persistent drag on overall profitability.